Serological Test for Influenza Disease Diagnostics Market Size (2024 – 2030)

The Global Serological Test for Influenza Disease Diagnostics Market was valued at USD 8.9 billion in 2023 and is projected to reach a market size of USD20.51 billion by 2030. Over the forecast period of 2024-2030, market is projected to grow at a CAGR of 12.6%.

When seasonal influenza A and B viruses are circulating in the surrounding population during accelerated influenza activity, testing for the influenza virus is no longer necessary to determine the medical prognosis of influenza in outpatients with suspected influenza. On the other hand, influenza virus testing can help clinical management when the results may affect clinical decisions about starting antiviral medication, using other diagnostic tests, or enforcing contamination prevention and influenza manipulation measures. It is no longer recommended to use serological testing for influenza when making medical decisions. Serological testing results for antibodies to influenza A or B viruses on a single serum sample cannot be properly interpreted, although being offered by certain commercial laboratories. A 4-fold or more elevation in influenza virus strain-specific antibodies can be detected by reliable testing at a small number of public fitness or research laboratories using matched acute and convalescent samples collected two to three weeks apart. Consequently, serological testing for influenza is no longer recommended for anything other than research and public health studies, and it no longer yields prompt results to aid in clinical decision-making.

Key Market Insights:

Multiplex assays, which can identify influenza as well as other respiratory viruses like COVID-19, are becoming more and more popular in hospitals, while PCR testing are still the gold standard for quickly diagnosing influenza. This demonstrates the increasing desire for more comprehensive diagnostic tools that increase effectiveness and resource efficiency.Due to the growing need for quick and decentralised testing, especially in primary care settings and for possible home usage, the global market for CLIA-waived point-of-care influenza diagnostics is anticipated to increase significantly. According to estimates from the World Health Organisation (WHO), there are around 1 billion cases of seasonal influenza worldwide each year. Serological assays can be extremely important in increasing access to influenza diagnostics in settings with low resources because of their possible cost-effectiveness when compared to certain other techniques. Even with recent advances, serological testing can occasionally yield unreliable findings, particularly in the early stages of illness. The necessity of developing serological tests further to increase their specificity and sensitivity for identifying influenza A and B strains.

Global Serological Test for Influenza Disease Diagnostics Market Drivers:

Increasing Influenza Rate and the Requirement for Easily Accessible Diagnostics
An ever-increasing illness burden presents a daunting challenge to the worldwide influenza epidemic. Influenza viruses spread mostly due to factors like population expansion and the world's growing interconnection via international travel. To properly detect and treat influenza, there must always be an adequate supply of diagnostic instruments due to its unrelenting growth. In this case, serological testing becomes an invaluable tool, especially in areas where access to cutting-edge technology is restricted. In contrast to certain diagnostic techniques that need specific tools and lab environments, serological testing provides a more convenient option. In environments with low resources, where specialised diagnostic infrastructure may be hard to come by, this accessibility is essential. Serological testing can be extremely helpful in preventing the spread of influenza and guaranteeing prompt treatment for individuals who become ill by offering a trustworthy diagnostic alternative in these areas.

Diagnostic Tests using Serology for Influenza in Developing Areas
The World Health Organisation estimates that there are an astounding 1 billion cases of seasonal influenza worldwide each year, making the burden of influenza a serious public health problem. Developing nations are disproportionately affected by this cost because they frequently lack the capacity to get cutting-edge diagnostic equipment. In this instance, serological testing provides a glimmer of optimism in the battle against influenza. Due to their inherent cost-effectiveness, serological assays have enormous potential to increase access to influenza diagnostics in these settings. Serological tests are less expensive to design and administer than certain other diagnostic techniques that need specialised facilities and costly equipment. In environments with low resources, where healthcare budgets are frequently squeezed, this affordability element is critical. Serological tests have the potential to empower healthcare professionals by facilitating faster identification of influenza infections, so enabling early treatment and perhaps halting the spread of epidemics. Apart from that, the possibility of creating point-of-care versions of serological tests increases their availability in areas with inadequate laboratory facilities. In conclusion, because serological tests are more affordable and have the potential to be used more widely, they can close the diagnosis gap in poor countries, resulting in better public health outcomes and more efficient management of influenza.

Global Serological Test for Influenza Disease Diagnostics Market Restraints and Challenges:

The global market for serological tests for influenza disease diagnostics has prospects, but there are also obstacles that must be overcome. Accuracy assurance is a major obstacle. Results from serological testing might be erroneous, particularly in the early stages of an illness when antibody levels are low. Inappropriate therapy and misdiagnosis may result from this. There are also restrictions on strain specificity. Certain influenza strains may be difficult for current testing to distinguish from one another, especially novel variations. This may impede precise diagnosis and make public health initiatives more difficult. Additionally, serological tests are less useful in circumstances needing quick findings since they are surpassed in speed and accuracy by more certain techniques like as PCR testing. It can be challenging to get insurance payment for serological tests, particularly for at-home testing, which may restrict certain patients' accessibility and affordability. For serological tests to reach their full potential and be more widely used in the worldwide influenza diagnostics industry, these obstacles must be overcome.

Global Serological Test for Influenza Disease Diagnostics Market Opportunities:

Prospective prospects exist for the future in the global market for serological tests for influenza disease diagnostics. First off, widespread at-home influenza testing may become possible with the development of more straightforward and user-friendly serological assays. This might potentially lessen the severity of sickness and its transmission rates by enabling people to receive a diagnosis and start treatment more quickly. Second, there is a great chance to develop serological tests that can identify a wider variety of influenza strains, including novel and developing variations. For influenza monitoring, this increased strain coverage would be important, improving public health readiness to fend against seasonal flu and possible pandemics. Lastly, significant progress towards developing serological assays capable of differentiating between an ongoing influenza illness and prior exposure would be transformative.

SEROLOGICAL TEST FOR INFLUENZA DISEASE DIAGNOSTICS MARKET REPORT COVERAGE:

Global Serological Test for Influenza Disease Diagnostics Market Segmentation: By Influenza Type

• Type A

• Type B

• Type C

According to the kind of influenza, in 2022 kind A influenza caused the most problems and spread the fastest. This virus is to blame for the global spread of a new illness and flu pandemics. Additionally, influenza A has been the primary cause of most epidemics, which are large-scale outbreaks of an infectious disease within a community at a certain period.

Global Serological Test for Influenza Disease Diagnostics Market - By End-Use

• Hospitals

• POCT

• Laboratories

The hospital category had the largest income share based on End-Use. Hospitalisation rates associated with seasonal influenza are high. The hospital stays demonstrate the disease's manageable severity. Because influenza can also exacerbate current fitness requirements or cause other issues that require hospitalisation. 40.6% of patients experienced pregnancy difficulties, 44% had cardiovascular disorders, and 44% had hypertension issues. Growing underlying clinical issues such autoimmune illnesses force patients to seek treatment at health centres. Advancements in technology are expected to simplify the monitoring process for the elderly population, particularly regarding the development of more advanced flu diagnostic tests and the combination of POCT and flu testing. POCT is also expected to increase flu testing in Asia Pacific countries' remote areas, where access to healthcare is scarce.

Global Serological Test for Influenza Disease Diagnostics Market Segmentation: By Region

• North America 

• Asia-Pacific 

• Europe 

• South America 

• Middle East and Africa

North America is regarded as the important region geographically and accounted for most of the income share. Over the course of the projection period, it is expected that the area will continue to play a prominent role. This growth can be linked to the presence of important actors as well as the expansion of government monitoring. Asia Pacific, mostly driven by China and India, has the fastest CAGR throughout the projected timeframe. The main factors contributing to the rise in the area are the large number of impacted individuals, the improvement of government cooperation, and the advancement of healthcare facilities. To address the issues, some South-East Asia-Pacific nations have teamed up with international organisations like the WHO. The most common issue encountered in the field is the shortage of flu-positive specimens.

COVID-19 Impact Analysis on the Global Serological Test for Influenza Disease Diagnostics Market:

The COVID-19 pandemic has had a significant negative influence on the serological test for influenza disease diagnostics market. The pandemic has altered the global medical care delivery system. The COVID-19 pandemic has had a significant impact on the influenza diagnostics industry. Unfavourable changes to regulations and policies, the shutdown of production facilities owing to lockdowns, and supply chain disruptions have all negatively impacted the market's expansion. The availability of influenza diagnostics products to end users has also declined because of restricted operations in the majority of businesses, inadequate support for research and instructional institutes, and difficulties in delivering necessary/post-sales offers because of lockdowns. Moreover, influenza and COVID-19 have many characteristics; both seasonal flu viruses (A and B) and COVID-19 are communicable and present with identical respiratory disease symptoms. Epidemics of influenza often occur around December through February. The COVID-19 pandemic also occurred during flu season, which led to a rise in the use of influenza tests at this time.  The COVID-19 pandemic has recently made the issue more critical. Flu testing has significantly increased across the United States. Patients continue to report confusing COVID-19 with the flu since these first symptoms are quite identical. The two viruses' corresponding fatality quotes and sequential intervals, however, differ. Due to the outbreak, rapid influenza diagnostic testing has increased in tandem with COVID-19 tests. The industry is expected to soar after advancements in point-of-care technology that combines influenza A and B testing with COVID-19 testing.

Recent Trends and Developments in the Global Serological Test for Influenza Disease Diagnostics Market:

Alongside the wider area of influenza diagnostics, the worldwide market for serological tests is also changing. The emergence of multiplex assays, such as the BD Veritor Plus System, which can detect respiratory viruses like COVID-19 in addition to influenza A and B, is one significant trend. Because of its effectiveness and capacity to identify a broader spectrum of disorders with a single test, this combination testing technique is becoming more and more common. There's also an increasing focus on creating point-of-care diagnostics that qualify for CLIA waivers. Without relying on centralised laboratories, these streamlined tests may be utilised at home or in doctor's offices to get speedier results. Furthermore, technological developments such as smaller devices and better immunoassay formats might lead to faster, more accurate, and more user-friendly influenza serological testing.

Key Players:

1. altona Diagnostics GmbH

2. Becton

3. bioMérieux SA

4. Coris BioConcept SPRL

5. DiaSorin SA

6. Dickinson and Company

7. ELITech Group

8. GenMark Diagnostics, Inc.

9. Genome Diagnostics, Pvt. Ltd.

10. Hologic, Inc.